Pharming Group N.V (PHAR) Gains from Investment Securities: 2020-2025
Historic Gains from Investment Securities for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $196.2 million.
- Pharming Group N.V's Gains from Investment Securities rose 36.88% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $707.3 million, marking a year-over-year increase of 21.89%. This contributed to the annual value of -$2,658 for FY2020, which is 100.00% down from last year.
- Pharming Group N.V's Gains from Investment Securities amounted to $196.2 million in Q3 2025, which was down 2.14% from $200.5 million recorded in Q2 2025.
- Over the past 5 years, Pharming Group N.V's Gains from Investment Securities peaked at $200.5 million during Q2 2025, and registered a low of $130,275 during Q3 2022.
- Moreover, its 3-year median value for Gains from Investment Securities was $146.5 million (2023), whereas its average is $158.2 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 99.92% in 2022, then spiked by 110,995.76% in 2023.
- Over the past 5 years, Pharming Group N.V's Gains from Investment Securities (Quarterly) stood at $147.9 million in 2021, then climbed by 0.29% to $148.3 million in 2022, then dropped by 1.20% to $146.5 million in 2023, then dropped by 17.04% to $121.5 million in 2024, then spiked by 36.88% to $196.2 million in 2025.
- Its Gains from Investment Securities was $196.2 million in Q3 2025, compared to $200.5 million in Q2 2025 and $189.1 million in Q1 2025.